Skip to main content

Tanezumab FDA Approval Status

Last updated by Judith Stewart, BPharm on March 27, 2020.

FDA Approved: No
Generic name: tanezumab
Company: Pfizer Inc.
Treatment for: Osteoarthritis

Tanezumab is a nerve growth factor (NGF) inhibitor in development for the treatment of patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics.

Development timeline for tanezumab

DateArticle
Mar 25, 2021Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Mar 25, 2021Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Mar  2, 2020U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
Apr 18, 2019Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Feb 19, 2019Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Oct 23, 2018Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
Jul 18, 2018Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Jun 13, 2017Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer